The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
NCT ID: NCT06540261
Last Updated: 2024-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
65 participants
INTERVENTIONAL
2021-09-23
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
NCT06547385
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
NCT06532344
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
NCT02337946
First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer
NCT01163396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ONO-7913＋ONO-4538＋FOLFOX＋Bev
ONO-7913
Specified dose on specified days
ONO-4538
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Levofolinate
Specified dose on specified days
Bevacizumab
Specified dose on specified days
ONO-7913＋ONO-4538＋FOLFOX＋Cet
ONO-7913
Specified dose on specified days
ONO-4538
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Levofolinate
Specified dose on specified days
Cetuximab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONO-7913
Specified dose on specified days
ONO-4538
Specified dose on specified days
Fluorouracil
Specified dose on specified days
Oxaliplatin
Specified dose on specified days
Levofolinate
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Cetuximab
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Life expectancy of at least 3 months
3. Patients with ECOG performance status 0 or 1
Exclusion Criteria
2. Patients with multiple primary cancers
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
St. Marianna University Hospital
Kawasaki, Kanagawa, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Kurashiki Central Hospital
Kurashiki, Okayama-ken, Japan
Kansai Medical University Hospital
Hirakata, Osaka, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Osaka, Japan
Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
Saitama Cancer Center
Shinden, Saitama, Japan
Cancer Institute Hospital of JFCR
Koto-Ku, Tokyo, Japan
National Cancer Center Hospital
Chūōku, Toyko, Japan
Chiba Cancer Center
Chiba, , Japan
National Hospital Organization Osaka National Hospital
Osaka, , Japan
Osaka General Medical Center
Osaka, , Japan
Osaka International Cancer Institute
Osaka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONO-7913-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.